A Phase II Trial of an Extended-Release siRNA Implant Targeting KRASG12D/V in Locally Advanced Pancreatic Cancer.

doi:10.1158/1078-0432.CCR-25-3189

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Community

Back to search

Article

A Phase II Trial of an Extended-Release siRNA Implant Targeting KRASG12D/V in Locally Advanced Pancreatic Cancer.

Clinical cancer research : an official journal of the American Association for Cancer Research - 16 Mar 2026

Alagesan Brinda, Varghese Anna M, Ang Celina, Gutierrez Martin, Kamar Moshe, Passhak Maria, Geva Ravit, Yarom Nirit, Lahav Maor, Ligresti Rosario, Khamaysi Iyad, Bhutani Manoop S, Phillips Adam, Matalon Shay, Pollack-Shragai Orit, Rom Dror, Shirvan Mitchell, Javle Milind M, Park Wungki, Yu Kenneth, Schwartz Carly, Golan Talia, Schattner Mark, O'Reilly Eileen M

Abstract excerpt

PURPOSE: Locally advanced pancreatic cancer (LAPC) accounts for 30% of pancreatic cancers. We assessed the efficacy and safety of a novel extended-release siRNA targeting KRASG12D/V mutations (siG12D-LODER) combined with chemotherapy in LAPC. PATIENTS AND METHODS: This two-cohort, phase II multicenter, open-label study (NCT01676259) evaluated siG12D-LODER with chemotherapy in patients with LAPC, regardless of...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Albumins

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Deoxycytidine

Share to Fluorouracil

Source

Open in PubMed Open full text

Identifiers

PMID: 41528981
DOI: 10.1158/1078-0432.CCR-25-3189
PMCID: PMC13380262

Genes

KRAS

Variants

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 2 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

A Phase II Trial of an Extended-Release siRNA Implant Targeting KRASG12D/V in Locally Advanced Pancreatic Cancer.PMID 41528981Read ↗

Mutant KRAS is a druggable target for pancreatic cancer.Semantic proximity Read ↗

KRAS Inhibition in Pancreatic Cancer: Pooled Efficacy and Safety Signals from Early-Phase StudiesSemantic proximity Read ↗

Efficacy and safety signals from early-phase studies of KRAS inhibition in pancreatic cancer.Semantic proximity Read ↗

Sotorasib in KRAS p.G12C-Mutated Advanced Pancreatic Cancer.Semantic proximity Read ↗

Noncoding RNAs in drug-resistant pancreatic cancer: A reviewSemantic proximity Read ↗

Co-targeting KRAS and Exportin1 as an effective therapeutic strategy for KRASG12D mutant pancreatic ductal adenocarcinomaSemantic proximity Read ↗

Nanoliposomal irinotecan with fluorouracil for the treatment of advanced pancreatic cancer, a single institution experience.Semantic proximity Read ↗

Targeted nanodelivery of siRNA against KRAS G12D inhibits pancreatic cancer.Semantic proximity Read ↗

Treatment of KRAS-Mutated Pancreatic Cancer: New Hope for the Patients?Semantic proximity Read ↗

Efficacy of a Small-Molecule Inhibitor of KrasG12D in Immunocompetent Models of Pancreatic Cancer.Semantic proximity Read ↗

Jorunnamycin A induces apoptosis in pancreatic ductal adenocarcinoma cells, spheroids, and patient-derived organoids by modulating KRAS-mediated survival pathways.Semantic proximity Read ↗

Ferritin-based nanocarrier delivery of KRAS G12D inhibitor in pancreatic adenocarcinoma cells and patient-derived organoids: A novel approach for treatment.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.